@article{open2951,
           month = {September},
           title = {Host factors subverted by Mycobacterium tuberculosis: Potential targets for host directed therapy},
          author = {Rashi Kalra and Drishti Tiwari and H Kitdorlang Dkhar and Ella Bhagyaraj and Rakesh Kumar and Anshu Bhardwaj and Pawan Gupta},
       publisher = {Informa healthcare},
            year = {2021},
            note = {The Copyright of this article belongs to Informa healthcare},
         journal = {International reviews of immunology},
        keywords = {Host directed therapy (HDT); host epigenetic machinery; host transcription factors (TFs); host-pathogen interaction; tuberculosis (TB)},
             url = {http://crdd.osdd.net/open/2951/},
        abstract = {Despite new approaches in the diagnosis and treatment of tuberculosis (TB), it continues to be a major health burden. Several immunotherapies that potentiate the immune response have come up as adjuncts to drug therapies against drug resistant TB strains; however, there needs to be an urgent appraisal of host specific drug targets for improving their clinical management and to curtail disease progression. Presently, various host directed therapies (HDTs) exist (repurposed drugs, nutraceuticals, monoclonal antibodies and immunomodulatory agents), but these mostly address molecules that combat disease progression.}
}